Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Banerjee, Soumya https://orcid.org/0000-0001-7748-9885
Abstract
I want to thank the Editor for bringing attention to the effect of a potential shortage of hydroxychloroquine (HCQ) on existing patients with autoimmune diseases during the current COVID-19 crisis [1]. The drug has shown some promising results against SARS-CoV-2, although more testing needs to be done. However, hydroxychloroquine is also an effective medication for patients with autoimmune disorders like systemic lupus erythematosus [2].
Description
Keywords
32 Biomedical and Clinical Sciences, 3202 Clinical Sciences
Journal Title
Lancet Rheumatology
Conference Name
Journal ISSN
2665-9913
2665-9913
2665-9913
Volume Title
2
Publisher
Elsevier BV
Publisher DOI
Rights
All rights reserved